NSE · BSE · Real-time

Breaking Corporate Events, Analysed in Real Time

High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.

All New Order Fund Raise Expansion Earning Call Regulatory Approval Production Started Product Launched
Tagged Pharmaceuticals
Jeena Sikho Lifecare Starts 100-Bed Ayurvedic Hospital Operations in Mathura
Production Started

Jeena Sikho Lifecare Starts 100-Bed Ayurvedic Hospital Operations in Mathura

Jeena Sikho Lifecare has officially launched operations at its new Sanskriti Ayurvedic P.G. Medical College & Hospital in Mathura, Uttar Pradesh. This 100-bed facility is part of the company's broader strategy to expand its Ayurvedic healthcare infrastructure across India.

Jeena Sikho Lifecare Limited
10 Jun 2026 4 min read
Wanbury Ltd Submits DMFs for Global API Launch; Patalganga Unit Receives Zero Observations
Product Launched

Wanbury Ltd Submits DMFs for Global API Launch; Patalganga Unit Receives Zero Observations

Wanbury Limited has initiated expanded regulatory submissions for the global launch of new Active Pharmaceutical Ingredients (APIs). The company filed Drug Master Files for Diphenhydramine HCl and Paroxetine HCl across several international markets while its Patalganga manufacturing facility successfully cleared a Korea MFDS audit.

Wanbury Ltd
9 Jun 2026 4 min read
Anlon Healthcare Targets ₹800 Cr Revenue by FY28 Following 43% Growth in FY26
Earning Call

Anlon Healthcare Targets ₹800 Cr Revenue by FY28 Following 43% Growth in FY26

Anlon Healthcare Limited reported a robust 42.98% year-on-year increase in FY26 revenue, reaching ₹172.22 Crore. The company has announced an aggressive expansion plan targeting up to ₹800 Crore in revenue by FY28, supported by ₹130 Crore in planned capital expenditure.

Anlon Healthcare Limited
9 Jun 2026 4 min read
Gujarat Themis Biosyn Board Approves ₹1,000 Crore Fund Raise via QIP and Preferential Issue
Fund Raise

Gujarat Themis Biosyn Board Approves ₹1,000 Crore Fund Raise via QIP and Preferential Issue

The Board of Directors of Gujarat Themis Biosyn has authorized a significant capital raise of up to ₹1,000 crore through Qualified Institutions Placement. In addition to the QIP, the company will initiate a preferential issue of equity shares to non-promoter investors to bolster its financial position.

Gujarat Themis Biosyn Ltd
6 Jun 2026 4 min read
Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market
Product Launched

Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market

Glenmark Pharmaceuticals Inc., USA, has announced the commercial launch of Lacosamide Injection USP, a generic version of Vimpat®. This move expands the company's injectable portfolio in the United States, targeting a market with approximately $15.2 million in annual sales as of April 2026.

Glenmark Pharmaceuticals Ltd
5 Jun 2026 4 min read
Alkem Laboratories Launches India's First Semaglutide Pre-Filled Syringes at ₹350
Product Launched

Alkem Laboratories Launches India's First Semaglutide Pre-Filled Syringes at ₹350

Alkem Laboratories has launched India's first semaglutide single-shot pre-filled syringes at a disruptive starting price of INR 350. This strategic expansion follows the company's March 2026 launch of injection pens and aims to lower entry barriers for patients managing Type 2 diabetes and obesity.

Alkem Laboratories Limited
2 Jun 2026 4 min read
Amanta Healthcare Commissions 10.8 MWp Solar Plant to Reduce Operational Costs
Production Started

Amanta Healthcare Commissions 10.8 MWp Solar Plant to Reduce Operational Costs

Amanta Healthcare has successfully commissioned a new 10.8 MWp solar power plant in Gujarat to meet its internal energy requirements. The facility became operational on May 30, 2026, marking a significant step toward energy self-sufficiency and operational cost reduction.

Amanta Healthcare Ltd
30 May 2026 4 min read
Sai Parenterals Secures ₹104.50 Cr Exclusive Anti-TB Supply Contract from Philippines
New Order

Sai Parenterals Secures ₹104.50 Cr Exclusive Anti-TB Supply Contract from Philippines

Sai Parenterals has bagged a ₹104.50 crore long-term purchase order from Philippines-based PILL CORP for the exclusive supply of anti-tuberculosis products. This ten-year contract marks a significant international expansion and provides substantial long-term revenue visibility for the newly listed pharmaceutical firm.

Sai Parenterals Ltd
28 May 2026 4 min read
Senores Pharmaceuticals Reports 108% PAT Growth in FY26; Eyes Strong FY27 Guidance
Earning Call

Senores Pharmaceuticals Reports 108% PAT Growth in FY26; Eyes Strong FY27 Guidance

Senores Pharmaceuticals delivered a significant financial beat for FY26, characterized by a 62% increase in revenue and a 108% rise in net profit. The company's strategic focus on the US regulated market and a doubling of its approved ANDA portfolio has positioned it for aggressive expansion in the coming fiscal year.

Senores Pharmaceuticals Limited
14 May 2026 5 min read